IM CANNABIS CORP (IMCC)
CA44969Q4060 - Common Stock
IMCC gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 194 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of IMCC have multiple concerns. IMCC is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year IMCC has reported negative net income.
In the past year IMCC had a positive cash flow from operations.
IMCC had negative earnings in each of the past 5 years.
In the past 5 years IMCC always reported negative operating cash flow.
1.2 Ratios
IMCC has a Return On Assets (-28.82%) which is in line with its industry peers.
IMCC has a Return On Equity of -216.04%. This is in the lower half of the industry: IMCC underperforms 71.35% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -28.82% | ||
| ROE | -216.04% | ||
| ROIC | N/A |
ROA(3y)-112.32%
ROA(5y)-148.76%
ROE(3y)-302.78%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of IMCC (12.87%) is comparable to the rest of the industry.
IMCC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 12.87% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
IMCC does not have a ROIC to compare to the WACC, probably because it is not profitable.
IMCC has more shares outstanding than it did 1 year ago.
The number of shares outstanding for IMCC has been increased compared to 5 years ago.
Compared to 1 year ago, IMCC has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -8.00, we must say that IMCC is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -8.00, IMCC is not doing good in the industry: 70.31% of the companies in the same industry are doing better.
The Debt to FCF ratio of IMCC is 5.69, which is a neutral value as it means it would take IMCC, 5.69 years of fcf income to pay off all of its debts.
IMCC's Debt to FCF ratio of 5.69 is amongst the best of the industry. IMCC outperforms 86.46% of its industry peers.
A Debt/Equity ratio of 2.24 is on the high side and indicates that IMCC has dependencies on debt financing.
IMCC has a worse Debt to Equity ratio (2.24) than 81.25% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.24 | ||
| Debt/FCF | 5.69 | ||
| Altman-Z | -8 |
ROIC/WACCN/A
WACC11.42%
2.3 Liquidity
A Current Ratio of 0.70 indicates that IMCC may have some problems paying its short term obligations.
IMCC has a worse Current ratio (0.70) than 95.31% of its industry peers.
IMCC has a Quick Ratio of 0.70. This is a bad value and indicates that IMCC is not financially healthy enough and could expect problems in meeting its short term obligations.
IMCC's Quick ratio of 0.52 is on the low side compared to the rest of the industry. IMCC is outperformed by 94.79% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.7 | ||
| Quick Ratio | 0.52 |
3. Growth
3.1 Past
IMCC shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -172.51%.
Looking at the last year, IMCC shows a decrease in Revenue. The Revenue has decreased by -2.23% in the last year.
The Revenue has been growing by 45.36% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-172.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-156.25%
Revenue 1Y (TTM)-2.23%
Revenue growth 3Y45.36%
Revenue growth 5YN/A
Sales Q2Q%12.23%
3.2 Future
Based on estimates for the next years, IMCC will show a small growth in Earnings Per Share. The EPS will grow by 1.27% on average per year.
The Revenue is expected to grow by 19.84% on average over the next years. This is quite good.
EPS Next Y-314.48%
EPS Next 2Y1.27%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year19.16%
Revenue Next 2Y19.84%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
IMCC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year IMCC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Compared to the rest of the industry, the Price/Free Cash Flow ratio of IMCC indicates a rather cheap valuation: IMCC is cheaper than 97.92% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 4.54 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.27%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for IMCC!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
IM CANNABIS CORP
NASDAQ:IMCC (11/29/2024, 7:42:55 PM)
After market: 3.75 -0.24 (-6.02%)3.99
+0.3 (+8.13%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap8.91M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -28.82% | ||
| ROE | -216.04% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 12.87% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover1.15
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.24 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 0.7 | ||
| Quick Ratio | 0.52 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-172.51%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-314.48%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-2.23%
Revenue growth 3Y45.36%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y